2020 Form 10-K Financial Statement
#000156459020044019 Filed on September 18, 2020
Income Statement
| Concept | 2020 | 2019 Q2 | 2019 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $4.510M | $1.940M | $4.740M |
| YoY Change | -4.85% | 223.33% | 23.76% |
| % of Gross Profit | |||
| Research & Development | $3.630M | $960.0K | $3.662M |
| YoY Change | -0.87% | -46.96% | -50.18% |
| % of Gross Profit | |||
| Depreciation & Amortization | $10.00K | $10.00K | $20.00K |
| YoY Change | -50.0% | 0.0% | |
| % of Gross Profit | |||
| Operating Expenses | $9.198M | $2.900M | $8.398M |
| YoY Change | 9.52% | 20.33% | -24.81% |
| Operating Profit | |||
| YoY Change | |||
| Interest Expense | $70.00K | $440.0K | $480.0K |
| YoY Change | -85.42% | 1366.67% | 1100.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $72.00K | -$130.0K | $350.3K |
| YoY Change | -79.44% | ||
| Pretax Income | -$9.130M | -$2.580M | -$8.050M |
| YoY Change | 13.42% | 8.4% | -27.74% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$9.126M | -$2.580M | -$8.048M |
| YoY Change | 13.39% | 8.4% | -27.75% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$0.87 | $3.16 | |
| Diluted Earnings Per Share | -$874.5K | -$868.7K | -$3.132M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 10.44M | 2.575M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 | 2019 Q2 | 2019 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $2.390M | $3.720M | $3.720M |
| YoY Change | -35.75% | -37.69% | -37.69% |
| Cash & Equivalents | $2.390M | $3.719M | $3.720M |
| Short-Term Investments | |||
| Other Short-Term Assets | $450.0K | $280.0K | $280.0K |
| YoY Change | 60.71% | -72.82% | -72.82% |
| Inventory | |||
| Prepaid Expenses | $280.2K | ||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $2.850M | $4.025M | $4.030M |
| YoY Change | -29.28% | -42.91% | -42.84% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | |||
| YoY Change | |||
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $80.00K | ||
| YoY Change | |||
| Total Long-Term Assets | $90.00K | $12.06K | $10.00K |
| YoY Change | 800.0% | -39.69% | -50.0% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $2.850M | $4.025M | $4.030M |
| Total Long-Term Assets | $90.00K | $12.06K | $10.00K |
| Total Assets | $2.940M | $4.037M | $4.040M |
| YoY Change | -27.23% | -42.9% | -42.86% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.010M | $1.740M | $1.740M |
| YoY Change | 15.52% | 17.57% | 17.57% |
| Accrued Expenses | |||
| YoY Change | |||
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $2.670M | $2.070M | $2.070M |
| YoY Change | 28.99% | 26.22% | 26.22% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $0.00 | $0.00 | |
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $2.670M | $2.070M | $2.070M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $2.670M | $2.070M | $2.070M |
| YoY Change | 28.99% | 26.2% | 26.22% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$60.58M | ||
| YoY Change | |||
| Common Stock | |||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $260.0K | $1.968M | $1.970M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $2.940M | $4.037M | $4.040M |
| YoY Change | -27.23% | -42.9% | -42.86% |
Cashflow Statement
| Concept | 2020 | 2019 Q2 | 2019 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$9.126M | -$2.580M | -$8.048M |
| YoY Change | 13.39% | 8.4% | -27.75% |
| Depreciation, Depletion And Amortization | $10.00K | $10.00K | $20.00K |
| YoY Change | -50.0% | 0.0% | |
| Cash From Operating Activities | -$7.928M | -$1.820M | -$6.327M |
| YoY Change | 25.3% | -28.06% | -35.76% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $0.00 | |
| YoY Change | -100.0% | ||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | $0.00 | $0.00 | |
| YoY Change | -100.0% | ||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 6.601M | 3.380M | 4.074M |
| YoY Change | 62.02% | -55.95% | |
| NET CHANGE | |||
| Cash From Operating Activities | -7.928M | -1.820M | -6.327M |
| Cash From Investing Activities | 0.000 | 0.000 | |
| Cash From Financing Activities | 6.601M | 3.380M | 4.074M |
| Net Change In Cash | -1.327M | 1.560M | -2.253M |
| YoY Change | -41.11% | -161.66% | 269.38% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$7.928M | -$1.820M | -$6.327M |
| Capital Expenditures | $0.00 | $0.00 | |
| Free Cash Flow | -$1.820M | -$6.327M | |
| YoY Change | -28.06% | -35.7% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q2 | us-gaap |
Liabilities
Liabilities
|
2674923 | |
| CY2019Q2 | us-gaap |
Liabilities
Liabilities
|
2069725 | |
| CY2020Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
11458 | |
| CY2020Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
56624048 | |
| CY2019 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3662056 | |
| CY2019 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4736440 | |
| CY2020 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001498382 | |
| CY2020 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--06-30 | |
| CY2020 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2020 | dei |
Document Type
DocumentType
|
10-K | |
| CY2020 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2020 | |
| CY2020 | dei |
City Area Code
CityAreaCode
|
858 | |
| CY2020 | dei |
Local Phone Number
LocalPhoneNumber
|
350-4364 | |
| CY2020 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
| CY2019Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
12062 | |
| CY2020Q2 | us-gaap |
Deferred Costs
DeferredCosts
|
84944 | |
| CY2020Q2 | us-gaap |
Assets
Assets
|
2938137 | |
| CY2020 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
| CY2020Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
2011058 | |
| CY2019Q2 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
325208 | |
| CY2020 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2020-06-30 | |
| CY2020 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2020Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2392402 | |
| CY2020Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
355580 | |
| CY2020 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
NV | |
| CY2020 | dei |
Entity File Number
EntityFileNumber
|
001-37823 | |
| CY2020 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
99-0360497 | |
| CY2020 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
12707 High Bluff Dr | |
| CY2020 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 200 | |
| CY2020 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
San Diego | |
| CY2020 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
| CY2020 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
92130 | |
| CY2020Q2 | ktra |
Taxes And Other Receivables Current
TaxesAndOtherReceivablesCurrent
|
9401 | |
| CY2019Q2 | ktra |
Taxes And Other Receivables Current
TaxesAndOtherReceivablesCurrent
|
26187 | |
| CY2020Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
2109 | |
| CY2020Q2 | ktra |
Voting Share
VotingShare
|
0 | |
| CY2019Q2 | ktra |
Voting Share
VotingShare
|
0 | |
| CY2020Q2 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
8524336 | |
| CY2019Q2 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
6588283 | |
| CY2020Q2 | ktra |
Preferred Stock Special Voting Shares Issued
PreferredStockSpecialVotingSharesIssued
|
0 | |
| CY2020Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2019Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
95000000 | |
| CY2019Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
3839358 | |
| CY2020 | dei |
Entity Registrant Name
EntityRegistrantName
|
Kintara Therapeutics, Inc. | |
| CY2020 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2020 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2020 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2020 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2020 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2019Q4 | dei |
Entity Public Float
EntityPublicFloat
|
7700000 | |
| CY2020Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
23543892 | |
| CY2020 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2020 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2020 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2019Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
3718758 | |
| CY2019Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
280248 | |
| CY2020Q2 | us-gaap |
Deferred Costs Current
DeferredCostsCurrent
|
93701 | |
| CY2020Q2 | us-gaap |
Assets Current
AssetsCurrent
|
2851084 | |
| CY2019Q2 | us-gaap |
Assets Current
AssetsCurrent
|
4025193 | |
| CY2019Q2 | us-gaap |
Assets
Assets
|
4037255 | |
| CY2019Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1744517 | |
| CY2019 | us-gaap |
Operating Expenses
OperatingExpenses
|
8398496 | |
| CY2020 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-2923 | |
| CY2020 | us-gaap |
Operating Expenses
OperatingExpenses
|
9198241 | |
| CY2019 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-17746 | |
| CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1967530 | |
| CY2019Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
4037255 | |
| CY2019Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2020Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-60578345 | |
| CY2019Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
21178 | |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9125916 | |
| CY2020Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
95000000 | |
| CY2020Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
11457928 | |
| CY2020 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3630024 | |
| CY2020 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4514520 | |
| CY2020 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
75248 | |
| CY2020 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
72325 | |
| CY2020 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P3Y | |
| CY2020 | us-gaap |
Payments For Software
PaymentsForSoftware
|
79910 | |
| CY2019 | us-gaap |
Payments For Software
PaymentsForSoftware
|
79910 | |
| CY2020 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
9953 | |
| CY2019 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
16349 | |
| CY2020 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2020 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| CY2019Q2 | ktra |
Preferred Stock Special Voting Shares Issued
PreferredStockSpecialVotingSharesIssued
|
1 | |
| CY2020 | ktra |
Merger Costs
MergerCosts
|
1053697 | |
| CY2019 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
-433503 | |
| CY2019 | us-gaap |
Payments Of Derivative Issuance Costs
PaymentsOfDerivativeIssuanceCosts
|
126186 | |
| CY2019 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
60704 | |
| CY2019 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
350275 | |
| CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8048221 | |
| CY2020 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
8616 | |
| CY2019 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
80431 | |
| CY2020 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-9134532 | |
| CY2019 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-8128652 | |
| CY2020 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.87 | |
| CY2019 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
3.16 | |
| CY2020 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
10444045 | |
| CY2019 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
2574692 | |
| CY2018Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5435223 | |
| CY2019 | ktra |
Issuance Of Shares And Warrants Net Of Issue Cost
IssuanceOfSharesAndWarrantsNetOfIssueCost
|
2386171 | |
| CY2019 | ktra |
Exercise And Exchange Of Warrants
ExerciseAndExchangeOfWarrants
|
720165 | |
| CY2019 | ktra |
Reclassification Of Derivative Liability To Equity
ReclassificationOfDerivativeLiabilityToEquity
|
492884 | |
| CY2019 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
13777 | |
| CY2019 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
23715 | |
| CY2019 | ktra |
Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
|
2 | |
| CY2019 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
426029 | |
| CY2019 | us-gaap |
Restricted Stock Expense
RestrictedStockExpense
|
526141 | |
| CY2019 | ktra |
Series Preferred Stock Dividends
SeriesPreferredStockDividends
|
-8356 | |
| CY2019 | us-gaap |
Profit Loss
ProfitLoss
|
-8048221 | |
| CY2020 | ktra |
Issuance Of Shares And Warrants Net Of Issue Cost
IssuanceOfSharesAndWarrantsNetOfIssueCost
|
6582966 | |
| CY2020 | ktra |
Exercise Of Pre Funded Warrants For Cash
ExerciseOfPreFundedWarrantsForCash
|
26550 | |
| CY2020 | ktra |
Exercise Of Warrants For Cash
ExerciseOfWarrantsForCash
|
25000 | |
| CY2020 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
13396 | |
| CY2020 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
287183 | |
| CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
494861 | |
| CY2020 | ktra |
Series Preferred Stock Dividends
SeriesPreferredStockDividends
|
-8356 | |
| CY2020 | us-gaap |
Profit Loss
ProfitLoss
|
-9125916 | |
| CY2019 | ktra |
Noncash Derivative Issue Costs
NoncashDerivativeIssueCosts
|
13495 | |
| CY2020 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
9953 | |
| CY2019 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
16349 | |
| CY2019 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
433503 | |
| CY2020 | ktra |
Issuance Of Stock For Services
IssuanceOfStockForServices
|
13396 | |
| CY2019 | ktra |
Issuance Of Stock For Services
IssuanceOfStockForServices
|
13777 | |
| CY2020 | ktra |
Increase Decrease In Fair Value Of Warrants Issued For Services
IncreaseDecreaseInFairValueOfWarrantsIssuedForServices
|
193482 | |
| CY2019 | ktra |
Increase Decrease In Fair Value Of Warrants Issued For Services
IncreaseDecreaseInFairValueOfWarrantsIssuedForServices
|
23715 | |
| CY2020 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
494861 | |
| CY2019 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
426029 | |
| CY2020 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
75332 | |
| CY2019 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-754682 | |
| CY2020 | ktra |
Increase Decrease In Taxes And Other Receivables
IncreaseDecreaseInTaxesAndOtherReceivables
|
-16786 | |
| CY2019 | ktra |
Increase Decrease In Taxes And Other Receivables
IncreaseDecreaseInTaxesAndOtherReceivables
|
-13332 | |
| CY2020 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
206597 | |
| CY2019 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
202000 | |
| CY2020 | us-gaap |
Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
|
338657 | |
| CY2019 | us-gaap |
Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
|
164779 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-7927516 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6327425 | |
| CY2020 | ktra |
Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
|
6582966 | |
| CY2019 | ktra |
Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
|
3362379 | |
| CY2020 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
51550 | |
| CY2019 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
720165 | |
| CY2020 | us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
8356 | |
| CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1326356 | |
| CY2019 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-2253237 | |
| CY2019Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
3718758 | |
| CY2019 | us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
8356 | |
| CY2020 | ktra |
Deferred Financing Costs
DeferredFinancingCosts
|
-25000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
6601160 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4074188 | |
| CY2018Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
5971995 | |
| CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
2392402 | |
| CY2020 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of operations, corporate history, and liquidity risk</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nature of operations</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) (the “Company”) is a clinical stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage, Phase 3-ready therapeutics - VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources.  The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates. </font></p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate history</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”). </font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On August 19, 2020 the Company completed its merger with Adgero Biopharmaceuticals Holdings, Inc. (“Adgero”). In conjunction with the Adgero merger, the Company changed its name to Kintara Therapeutics, Inc.</font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero, a Delaware corporation, which are clinical stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc., formerly a wholly-owned subsidiary of Adgero.</font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">References to the Company refer to the Company and its wholly-owned subsidiaries.</font></p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity risk and management plans</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">These consolidated financial statements have been prepared on a going concern basis which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business.</font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">For the year ended June 30, 2020, the Company reported a loss of $9,125,916, and a negative cash flow from operations of $7,927,516. The Company had an accumulated deficit of $69,721,233 as of June 30, 2020. As of June 30, 2020, the Company has cash and cash equivalents on hand of $2,392,402. The Company is in the clinical stage and has not generated any revenues to-date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized, or partnered, which may not ever occur. In the future, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. The Company may tailor its drug development programs based on the amount of funding the Company is able to raise in the future.</font> </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">These circumstances had indicated substantial doubt existed about the Company’s ability to continue as a going concern. Subsequent to June 30, 2020, the Company completed a private placement in three closings for gross proceeds of approximately $25 million, or net proceeds of approximately $21.7 million (note 11). The Company believes that based on its current estimates, the cash on hand at June 30, 2020 of $2,392,402 and the proceeds from the private placement, will be sufficient to fund its planned operations beyond the next year from the date these consolidated financial statements are issued. As a result, substantial doubt about the Company’s ability to continue as a going concern has been alleviated. However, the coronavirus (“COVID-19”) pandemic has created significant economic uncertainty and volatility in the credit and capital markets. The ultimate impact of the COVID-19 pandemic on the Company’s ability to raise additional capital in the future is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak and any new information which may emerge concerning the severity of the COVID-19 pandemic.</font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">These financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.</font></p> | |
| CY2020 | ktra |
Amended Articles Of Incorporation
AmendedArticlesOfIncorporation
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amended articles of incorporation</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 26, 2019, the Company amended its articles of incorporation to increase the number of authorized shares of common stock from 7,000,000 to 95,000,000 shares.</p> | |
| CY2020 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the fair value of the derivative liabilities, the valuation of equity instruments issued for services, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</p> | |
| CY2020 | ktra |
Accruals For Research And Development Expenses And Clinical Trials Policytext Block
AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicytextBlock
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accruals for research and development expenses and clinical trials</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants, and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects of the expenses. The Company determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the years ended June 30, 2020 and 2019, there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials.</p> | |
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
701691 | |
| CY2020 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
494861 | |
| CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1559199 | |
| CY2020 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
25000000 | |
| CY2020 | ktra |
Net Proceeds From Private Placement
NetProceedsFromPrivatePlacement
|
21700000 | |
| CY2019Q2 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
Certificate of Change with the Secretary of State of Nevada that effected a 1-for-10 (1:10) reverse stock split of its common stock, par value $0.001 per share, which became effective on May 8, 2019. | |
| CY2019Q2 | us-gaap |
Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
|
Pursuant to the Certificate of Change, the Company’s authorized common stock was decreased in the same proportion as the split resulting in a decrease from 70,000,000 authorized shares of common stock to 7,000,000 shares authorized. The par value of its common stock was unchanged at $0.001 per share, post-split. All common shares, warrants, stock options, conversion ratios, and per share information in these consolidated financial statements give retroactive effect to the 1-for-10 reverse stock split. The Company’s authorized and issued preferred stock was not affected by the split. | |
| CY2019Q2 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.1 | |
| CY2019Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q2 | us-gaap |
Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
|
0 | |
| CY2020Q2 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
0 | |
| CY2019Q2 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
0 | |
| CY2019 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
426029 | |
| CY2018Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
138160 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
30000 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
83170 | |
| CY2019Q2 | us-gaap |
Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
|
0 | |
| CY2020Q2 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
84944 | |
| CY2020Q2 | ktra |
Deferred Loan Costs
DeferredLoanCosts
|
93701 | |
| CY2020Q2 | us-gaap |
Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
|
178645 | |
| CY2018Q2 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
1117 | |
| CY2019 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
925270 | |
| CY2019 | ktra |
Reclassification Of Derivative Liability To Equity Upon Amendment Of Dividend Warrants
ReclassificationOfDerivativeLiabilityToEquityUponAmendmentOfDividendWarrants
|
-433503 | |
| CY2019 | ktra |
Reclassification To Equity Upon Exercise Of Warrants
ReclassificationToEquityUponExerciseOfWarrants
|
-492884 | |
| CY2020Q2 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
0 | |
| CY2019Q2 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
0 | |
| CY2020 | ktra |
Issuance Of Agent Warrants
IssuanceOfAgentWarrants
|
2180 | |
| CY2019 | ktra |
Issuance Of Agent Warrants
IssuanceOfAgentWarrants
|
2180 | |
| CY2020 | ktra |
Agent Warrants Issued To Purchase Of Common Stock
AgentWarrantsIssuedToPurchaseOfCommonStock
|
2180 | |
| CY2019 | ktra |
Agent Warrants Issued To Purchase Of Common Stock
AgentWarrantsIssuedToPurchaseOfCommonStock
|
2180 | |
| CY2020Q2 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
25000 | |
| CY2019Q2 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
207500 | |
| CY2019Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2020 | ktra |
Underwritten Public Offering Description
UnderwrittenPublicOfferingDescription
|
The Company closed on the sale of (i) 4,895,000 shares of its common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 2,655,000 shares of Common Stock and (iii) common warrants to purchase an aggregate of 7,762,500 shares of Common Stock (“2020 Investor Warrants”), including 800,000 shares of Common Stock and 2020 Investor Warrants to purchase an aggregate of 1,012,500 shares of Common Stock sold pursuant to a partial exercise by the underwriters of the underwriters’ option to purchase additional securities, in the Company’s underwritten public offering (the “Offering”). Each share of Common Stock or PFW, as applicable, was sold together with a 2020 Investor Warrant to purchase one share of Common Stock at a combined effective price to the public of $1.00 per share of Common Stock and accompanying 2020 Investor Warrant. | |
| CY2020Q2 | ktra |
Common Stock Issued Under2017 Plan
CommonStockIssuedUnder2017Plan
|
491817 | |
| CY2019 | ktra |
Performance Stock Units Description
PerformanceStockUnitsDescription
|
The PSUs vest at various fully diluted market capitalization levels with full vesting occurring upon the later of one year from the grant date and the Company achieving a fully diluted market capitalization of at least $500 million for five consecutive business days. | |
| CY2019Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
84990 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1291016 | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
499748 | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
|
18750 | |
| CY2020Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
857508 | |
| CY2018Q2 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
|
14.39 | |
| CY2019 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice
|
6.10 | |
| CY2019 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice
|
14.51 | |
| CY2019Q2 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
|
11.35 | |
| CY2020 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice
|
0.63 | |
| CY2020 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice
|
1.87 | |
| CY2020 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Forfeited Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice
|
0.61 | |
| CY2020Q2 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
|
0.98 | |
| CY2018Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
7.63 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.56 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
|
7.65 | |
| CY2019Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
5.82 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.40 | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
|
1.12 | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
|
0.49 | |
| CY2020Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
0.52 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
2580676 | |
| CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
| CY2020 | ktra |
Non Cash Issue Costs
NonCashIssueCosts
|
182257 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
11870922 | |
| CY2019Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
10823529 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
|
17925 | |
| CY2019Q2 | us-gaap |
Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
|
17925 | |
| CY2020Q2 | ktra |
Deferred Tax Assets Financing Cost
DeferredTaxAssetsFinancingCost
|
221276 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
604489 | |
| CY2019Q2 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
534398 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
534355 | |
| CY2019Q2 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
484135 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
13248967 | |
| CY2019Q2 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
11859987 | |
| CY2020Q2 | ktra |
Deferred Tax Liabilities Scientific Research And Development
DeferredTaxLiabilitiesScientificResearchAndDevelopment
|
88929 | |
| CY2019Q2 | ktra |
Deferred Tax Liabilities Scientific Research And Development
DeferredTaxLiabilitiesScientificResearchAndDevelopment
|
81386 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
13160038 | |
| CY2019Q2 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
11778601 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
13160038 | |
| CY2019Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
11778601 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
||
| CY2019Q2 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
||
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-1916442 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-1690126 | |
| CY2020 | ktra |
Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
|
142523 | |
| CY2019 | ktra |
Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
|
-527532 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
-239465 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
-429531 | |
| CY2020 | ktra |
Income Tax Reconciliation Effect Of Foreign Exchange Rates
IncomeTaxReconciliationEffectOfForeignExchangeRates
|
347510 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
|
38252 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
|
39807 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
322689 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
106320 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
1381437 | |
| CY2019 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
| CY2020Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
|
6700000 | |
| CY2020 | ktra |
Percentage Of Taxable Income Limitation On No Ls
PercentageOfTaxableIncomeLimitationOnNOLs
|
0.80 | |
| CY2020 | us-gaap |
Tax Credit Carryforward Description
TaxCreditCarryforwardDescription
|
expire between 2029 and 2040 | |
| CY2020 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | |
| CY2020 | us-gaap |
Open Tax Year
OpenTaxYear
|
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 | |
| CY2020 | ktra |
Minimum Cumulative Percentage Of Change In Ownership As Condition To Offset Taxable Income Or Tax
MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax
|
0.50 | |
| CY2020 | ktra |
Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
|
P3Y | |
| CY2020 | ktra |
Manufacturing And Clinical Study Management Related Loan Term
ManufacturingAndClinicalStudyManagementRelatedLoanTerm
|
P1Y | |
| CY2020 | ktra |
Manufacturing And Clinical Study Management Related Cost
ManufacturingAndClinicalStudyManagementRelatedCost
|
1419520 | |
| CY2020 | ktra |
Clinical Development Research Deposits
ClinicalDevelopmentResearchDeposits
|
41938 | |
| CY2020 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
40130 | |
| CY2019 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
52926 | |
| CY2020 | us-gaap |
Dividends Preferred Stock Stock
DividendsPreferredStockStock
|
8616 | |
| CY2019 | us-gaap |
Dividends Preferred Stock Stock
DividendsPreferredStockStock
|
80431 | |
| CY2019 | ktra |
Non Cash Issue Costs
NonCashIssueCosts
|
52899 | |
| CY2019 | ktra |
Issue Costs In Accounts Payable
IssueCostsInAccountsPayable
|
64432 | |
| CY2020 | ktra |
Deferred Costs In Accounts Payable
DeferredCostsInAccountsPayable
|
59944 | |
| CY2020 | ktra |
Warrants Issued As Deferred Costs
WarrantsIssuedAsDeferredCosts
|
93701 | |
| CY2019 | ktra |
Reclassification Of Derivative Liability To Equity Upon Exercise Of Warrants
ReclassificationOfDerivativeLiabilityToEquityUponExerciseOfWarrants
|
492884 | |
| CY2020 | ktra |
Conversion Of Series B Preferred Stock Shares To Common Stock
ConversionOfSeriesBPreferredStockSharesToCommonStock
|
174407 | |
| CY2019 | ktra |
Conversion Of Series B Preferred Stock Shares To Common Stock
ConversionOfSeriesBPreferredStockSharesToCommonStock
|
1447576 | |
| CY2020 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
||
| CY2019 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
||
| CY2020 | us-gaap |
Interest Paid Net
InterestPaidNet
|
||
| CY2019 | us-gaap |
Interest Paid Net
InterestPaidNet
|
||
| CY2020 | us-gaap |
Concentration Risk Credit Risk Financial Instrument Maximum Exposure
ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
|
9401 | |
| CY2020 | ktra |
Concentration Risk Credit Risk Uninsured Amount Of Cash
ConcentrationRiskCreditRiskUninsuredAmountOfCash
|
2232270 | |
| CY2020Q2 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
160132 | |
| CY2020Q2 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
2232270 |
